Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

View website    Save this grant

Next deadline: Oct 5, 2022

Later deadlines: Feb 5, 2023, Jun 5, 2023, Oct 5, 2023

Grant amount: Unspecified amount

Fields of work: Cancer/Oncology

Applicant type: For-Profit Business, Government Entity, Indigenous Group, Nonprofit

Funding uses: Research

Location of project: Preferred: United States Other eligible locations: Anywhere in the world

Location of residency: Preferred: United States Other eligible locations: Anywhere in the world


This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that integrate imaging, biomarkers, digital pathomics, glycomics, metabolomics, other omic information and/or meta data obtained from platforms including but not limited to lower resolution diagnostic acquisitions and systemic biomarker results to high resolution single-cell analytics / imaging applied to the characterization of heterogeneous cell populations within tumor for improving current approaches for:

  • the early detection of organ confined premetastatic aggressive cancer, and, 
  • identifying precancerous lesions associated with a subsequent lethal phenotype.

This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions by improving detection sensitivity and specificity of integrated multiparametric platforms. For example, N-dimensional co-registered, cross-correlated imaging data integrated with multiplexed biomarker results and/or digital pathomics or glycomic, or metabolomic imaging using analytic strategies such as artificial intelligence or virtual reality visualization techniques. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to  improve diagnostic performance by developing methodology for the early identification of potentially lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and to reduce false positives and false negatives.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

Other Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih)

This page was last reviewed April 24, 2022 and last updated April 24, 2022